Not Yet RecruitingPhase 2ACTRN12606000405516

Atorvastatin for Renal Protection After Cardiopulmonary Bypass

A phase II randomised, double-blind, placebo-controlled study of the effect of atorvastatin on postoperative renal function in patients undergoing elective cardiopulmonary bypass

Sponsor

Austin Hospital, Department of Intensive Care

Enrollment

102 participants

Start Date

Dec 1, 2006

Study Type

Interventional

Conditions

Cardiac surgery with cardiopulmonary bypass

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether the cholesterol-lowering drug atorvastatin (a statin) can protect the kidneys after heart surgery that uses a heart-lung bypass machine. Adults aged 18 and older having elective heart surgery with at least one risk factor for kidney problems after surgery may join.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

atorvastatin 40mg orally starting morning of surgery pre-pump and the same dose continued daily orally for 3 days post-operatively

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000405516